Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Benefit Of Systemic Therapy In Mindact Patients With Small, Er-positive, Her2-negative Breast Cancers.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Benefit Of Systemic Therapy In Mindact Patients With Small, Er-positive, Her2-negative Breast Cancers.

Related Experiment Video

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

6.3K

Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers.

Florentine S Hilbers1, Coralie Poncet2, Konstantinos Tryfonidis2

  • 1Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.

NPJ Breast Cancer
|November 3, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

This study suggests small, genomic high-risk breast cancers may not benefit from chemotherapy. Endocrine therapy improved outcomes for both genomic high-risk and low-risk patients, indicating its value in early-stage HR+, HER2- breast cancer treatment.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K

Related Experiment Videos

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

6.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K

Area of Science:

  • Oncology
  • Genomics
  • Clinical Trials

Background:

  • Small, hormone receptor-positive (HR+), HER2-negative (HER2-) lymph node-negative breast cancers have low recurrence rates, leading to underrepresentation in systemic therapy trials.
  • The benefit of systemic therapy in this specific patient group remains uncertain due to limited trial data.

Purpose of the Study:

  • To explore the efficacy of systemic therapy, specifically chemotherapy, in patients with small (T1ab), HR+, HER2-, lymph node-negative breast cancer.
  • To analyze the impact of genomic risk classification versus clinical risk on treatment outcomes in this patient population.

Main Methods:

  • An exploratory analysis of MINDACT trial data (NCT00433589) involving 715 patients with HR+, HER2-, T1abN0 breast cancer.
  • Patients with discordant clinical and MammaPrint genomic risk were randomized to chemotherapy based on either risk assessment.
  • Outcomes were assessed based on 8-year distant metastasis-free survival (DMFS) and disease-free survival (DFS).

    • Main Results:

    • In genomic high-risk tumors, 8-year DMFS was 92.9% compared to 95.0% for genomic low-risk tumors.
    • For genomic high-risk tumors, chemotherapy showed no significant benefit (8-year DMFS 89.2% with chemo vs. 94.1% without).
    • Endocrine therapy was associated with improved outcomes in genomic low-risk tumors (8-year DMFS 96.1% with endocrine therapy vs. 92.9% without).

    Conclusions:

    • Patients with small, genomic high-risk HR+, HER2- breast cancer may not benefit from adjuvant chemotherapy.
    • Endocrine therapy demonstrated improved outcomes across genomic risk categories, suggesting its continued importance in managing early-stage HR+, HER2- breast cancer.